 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- ||| efocipegtrutide (HM15211) / Hanmi
Enrollment closed, Trial completion date: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (clinicaltrials.gov) - Jul 3, 2025
P2, N=215, Active, not recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Jul 2026
- | Journal: Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. (Pubmed Central) - Apr 5, 2025
The creation of multi-targeting incretin-based synthetic peptides provides opportunities for improved management of type 2 diabetes and obesity as well as new therapeutic approaches to an expanding list of associated co-morbidities. The aim of the review is to acquaint the reader with developments in the field from 2023 to the present (February 2025).
- || efocipegtrutide (HM15211) / Hanmi
Trial completion date, Trial primary completion date: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (clinicaltrials.gov) - Feb 19, 2025
P2, N=240, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
The aim of the review is to acquaint the reader with developments in the field from 2023 to the present (February 2025). Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> May 2026
- || efocipegtrutide (HM15211) / Hanmi
Trial completion date, Trial primary completion date: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (clinicaltrials.gov) - Jan 23, 2025
P2, N=240, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> May 2026 Trial completion date: Nov 2026 --> Nov 2025 | Trial primary completion date: May 2026 --> May 2025
- || efocipegtrutide (HM15211) / Hanmi
Trial completion date, Trial primary completion date: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (clinicaltrials.gov) - Jan 3, 2025
P2, N=240, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
Trial completion date: Nov 2026 --> Nov 2025 | Trial primary completion date: May 2026 --> May 2025 Trial completion date: Nov 2025 ->Nov 2026 | Trial primary completion date: May 2025 --> May 2026
- efocipegtrutide (HM15211) / Hanmi
GLUCAGON ENGAGEMENT IS ESSENTIAL FOR THE DIRECT ANTI-INFLAMMATION AND ANTI-FIBROSIS EFFECT OF EFOCIPEGTRUTIDE IN TAA-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_806;
These result demonstrate that GCG engagement could play a crucial role in managing hepatic inflammation and fibrosis. P2b study in biopsy confirmed MASH patients is currently ongoing to assess the clinical relevance of these findings.
- || efocipegtrutide (HM15211) / Hanmi
Trial completion: A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide) (clinicaltrials.gov) - May 20, 2024
P1, N=41, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
P2b study in biopsy confirmed MASH patients is currently ongoing to assess the clinical relevance of these findings. Unknown status --> Completed
- || efocipegtrutide (HM15211) / Hanmi
Clinical, P2 data, Journal, Biopsy: A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study. (Pubmed Central) - Jun 14, 2023
An interim analysis is planned after 15 patients/group complete 26?weeks of treatment, after which one HM15211 dose group will be discontinued based on safety and efficacy risk-to-benefit analysis; patients of the dropped dosing arm will be re-randomized into 2 remaining HM15211 groups. The adaptive design study of HM15211 minimizes the number of patients to be exposed to a liver biopsy while optimizing the sample size of patients exposed to safe and effective doses of HM15211 to inform ideal dose for further clinical development in NASH.
- efocipegtrutide (HM15211) / Hanmi
Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_649;
Notably, greater improvement effect over semaglutide and tirzepatide highlights the potential benefit of simultaneous use of GCG, GIP, and GLP-1. Thus, efocipegtrutide could be a novel therapeutic option for fibrosis due to NASH.
- efocipegtrutide (HM15211) / Hanmi
Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_592;
These results are consistent with previous study results in various NASH/fibrosis animal models, in which further reinforcing the robust anti-fibrotic effect of efocipegtrutide via simultaneous action of GCG, GIP, and GLP-1. Human study is ongoing to assess the clinical relevance of these findings.
- efocipegtrutide (HM15211) / Hanmi
Anti-fibrotic Potential of a Novel Long-acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Idiopathic Pulmonary Fibrosis (Walter E. Washington Convention Center, Area J, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_5621;
HM15211 could possess therapeutic potential for IPF with improved treatment effects over current standard of care. On-going mechanistic studies will elucidate the underlying mode of actions, and human study should be followed up to assess the clinical relevance of these findings.
- HM15211 / Hanmi
EFFECTS OF HM15211, A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, ON ANTI-INFLAMMATION AND ANTI-FIBROSIS IN TAA-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSIS () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1232;
Together with previous results, generalized anti-inflammatory and -fibrotic effects of HM15211 were corroborated. Thus, HM15211 could be a novel therapeutic option for fibrosis due to NASH.
- || efocipegtrutide (HM15211) / Hanmi
Trial completion date, Trial primary completion date: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (clinicaltrials.gov) - Jul 18, 2022
P2, N=217, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
Thus, HM15211 could be a novel therapeutic option for fibrosis due to NASH. Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Sep 2022 --> May 2025
- HM15211 / Hanmi
Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of idiopathic pulmonary fibrosis (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_955;
HM15211 could possess therapeutic potential for IPF with improved treatment effects over current standard of care. On-going mechanistic studies will elucidate the underlying mode of actions, and human study should be followed up (required) to assess the clinical relevance of these findings.
- HM15211 / Hanmi
Anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in TAA induced mouse model of liver injury and fibrosis (Short Oral Discussion Area) - Jul 9, 2022 - Abstract #EASD2022EASD_695;
Thus, HM15211 could be a novel therapeutic option for fibrosis caused by NASH. Human study is ongoing to assess the clinical relevance of these promising results.
- HM15211 / Hanmi
Direct Anti-Inflammatory and Antifibrotic Effects of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist, HM15211, in Thioacetamide-Induced Mouse Model of Liver Injury and Fibrosis (Poster Hall (Halls D-E); Board No. 735) - May 11, 2022 - Abstract #ADA2022ADA_1859;
Thus, HM15211 could be a novel therapeutic option for fibrosis due to NASH. Human study is ongoing to assess the clinical relevance of these findings.
- HM15211 / Hanmi
Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF (Poster Hall (Halls D-E); Board No. 754) - May 11, 2022 - Abstract #ADA2022ADA_1468;
Notably, HM15211 (61%) showed more improved survival rate than NINT (33%), and PIRF (28%), suggesting potential superiority of HM15211 over current IPF drugs.In conclusion, HM15211 may be a novel therapeutic potential for pulmonary fibrosis over current standard of care for IPF. Further evidences from the mechanistic studies will shed light on a direct inhibitory effect of HM15211 on pulmonary fibrosis.
- HM15211 / Hanmi
Direct anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in thioacetamide-induced mouse model of liver injury and fibrosis (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1114;
Together with previous results, generalized anti-inflammatory and -fibrotic effects of HM15211 were corroborated. Thus, HM15211 could be a novel therapeutic option for fibrosis due to NASH.
- HM15211 / Hanmi
Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/fibrosis (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1113;
Notably, DEG analysis supports the basis for multi-target engagement effects of HM15211. Thus, HM15211 might be a novel therapeutic option for NASH and fibrosis.
- HM15211 / Hanmi
DIRECT ANTI-INFLAMMATORY AND ANTI- FIBROTIC EFFECTS OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, HM15211, IN THIOACETAMIDE-INDUCED MOUSE MODEL OF LIVER INJURY AND FIBROSIS () - Mar 3, 2022 - Abstract #NASHTAG2022NASH_TAG_89;
Together with previous results, generalized anti-inflammatory and -fibrotic effects of HM15211 were corroborated. Thus, HM15211 could be a novel therapeutic option for fibrosis due to NASH.
- | Journal: Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. (Pubmed Central) - Jan 27, 2022
There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonism, which have proved to limit morbidity and mortality in type 2 diabetes.Areas covered: This review provides an overview of current compounds containing GLP-1 receptor agonism in clinical development for obesity, with mono-activity at the GLP-1 receptor (PF-0688296, glutazumab, semaglutide) or engaging one or more other endogenous hormonal systems involved in energy balance and metabolism, including glucagon, oxyntomodulin, glucose-dependent inhibitory peptide and amylin (CT-868, CT-388, AMG 133, tirzepatide, NNC9204-1177, JNJ-54728518, SAR425899, pegapamodutide, MK8521, cotadutide, efinopegdutide, BI-456906, cagrilintide + semaglutide 2,4 mg, HM15211, NNC9204-1706).Expert opinion: Many novel compounds employing GLP-1 receptor agonism are in clinical development. Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of novel anti-obesity compounds.
- ||| efocipegtrutide (HM15211) / Hanmi
Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (clinicaltrials.gov) - Jan 11, 2022
P2, N=217, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of novel anti-obesity compounds. N=112 --> 217 | Trial completion date: Dec 2022 --> Nov 2024 | Trial primary completion date: Mar 2022 --> Sep 2022
- HM15211 / Hanmi
[VIRTUAL] STUDY ON MULTI-TARGET ENGAGEMENT EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, HM15211, IN ANIMAL MODEL OF NASH () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2051;
Therefore, HM15211 may be a novel therapeutic option for NASH treatment. Efficacy study in biopsy proven NASH subjects is ongoing to assess the clinical relevance of these finding.
- HM15211 / Hanmi
[VIRTUAL] ANTI-FIBROTIC POTENTIAL OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, HM15211, IN PRECLINICAL MODELS OF FIBROSIS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1985;
Hence, mechanistic studies highlight direct inhibitory effect of HM15211 on HSC activation. Human efficacy study is ongoing to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Anti-fibrotic potential of a novel long-acting glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of fibrosis (Rome Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_856;
Based on these results, HM15211 may be a novel therapeutic option for liver fibrosis in addition to NASH itself. On-going human efficacy study will assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in animal model of NASH (Paris Hall) - Jul 13, 2021 - Abstract #EASD2021EASD_825;
Considering more benefits of HM15211 over other incretin analogs and FXR agonist for NASH treatment, HM15211 may be a novel therapeutic option for NASH. Efficacy study in biopsy proven NASH patients is ongoing to assess the clinical relevance of these finding.
- HM15211 / Hanmi
[VIRTUAL] Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Fibrosis () - May 29, 2021 - Abstract #ADA2021ADA_1032;
Hence, related mechanistic studies further highlight direct inhibitory effect of HM15211 on HSC activation. On-going human efficacy study will assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Multitarget Engagement Effect of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Animal Model of NASH () - May 29, 2021 - Abstract #ADA2021ADA_1031;
Therefore, HM15211 may be a novel therapeutic option for NASH. Efficacy study in biopsy proven NASH patients is ongoing to assess the clinical relevance of these finding.
- HM15211 / Hanmi
[VIRTUAL] Study on multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_905;
Therefore, HM15211 may be a novel therapeutic option for NASH treatment. Efficacy study in biopsy proven NASH subjects is ongoing to assess the clinical relevance of these finding.
- HM15211 / Hanmi
[VIRTUAL] Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical models of fibrosis (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_902;
Hence, mechanistic studies highlight direct inhibitory effect of HM15211 on HSC activation. Human efficacy study is ongoing to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Potential effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical model of cholestatic liver disease (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_593;
In BDL mice, the desired treatment effects of HM15211 are well-corroborated. These results warrant further evaluation for therapeutic potential of HM15211 in PSC and PBC.
- HM15211 / Hanmi
ANTI-FIBROTIC EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST (HM15211) IN BDLINDUCED MOUSE MODEL OF LIVER FIBROSIS () - Mar 11, 2021 - Abstract #NASHTAG2021NASH-TAG_105;
Hence, invitro mechanistic study results along with reduced blood level of TGF-β in vivo suggest that negative regulation of HSC activation is essential for fibrosis improvement by HM15211. Further studies are needed to assess the clinical relevance of these findings.
- HM15211 / Hanmi
HM15211, A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, EXHIBITS ANTI-INFLAMMATORY AND ANTI-FIBROTIC EFFECTS IN AMLN/TAA INDUCED MOUSE MODEL OF LIVER INFLAMMATION AND FIBROSIS () - Mar 11, 2021 - Abstract #NASHTAG2021NASH-TAG_104;
Together with the results in DIO mice, our result suggest that HM15211 may be a novel therapeutic option for NASH and fibrosis by optimally conferring pharmacologic effects of Glucagon, GIP, and GLP-1. Human efficacy study in biopsy-proven NASH subjects is on-going to assess the clinical relevance of these findings.
- HM15211 / Hanmi
THERAPEUTIC EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST (HM15211) IN CDHFD-INDUCED NASH AND FIBROSIS MICE () - Mar 11, 2021 - Abstract #NASHTAG2021NASH-TAG_103;
Hence, more efficacy than acylated GLP-1/GIP further highlight the potential benefits of added glucagon engagement for the treatment of NASH and fibrosis. These results warrant on-going clinical study in biopsy proven NASH patients for human efficacy translation.
- HM15211 / Hanmi
AN ONGOING PHASE 2B STUDY OF HM15211, A NOVEL GLP-1/GIP/GLUCAGON TRIPLE-RECEPTOR CO-AGONIST, IN NONALCOHOLIC STEATOHEPATITIS SUBJECTS () - Mar 11, 2021 - Abstract #NASHTAG2021NASH-TAG_89;
Furthermore, we introduced a protocol driven risk-mitigation algorithms for management of alternations in glycemic control that may occur in the context of a NASH study. This adaptive phase 2b design can help in identifying the most efficacious and safe dose(s) of HM15211 in subjects with NASH and expedite the future pivotal trial.
- HM15211 / Hanmi
HM15211, A NOVEL GLP-1/GIP/GLUCAGON TRIPLE-RECEPTOR CO-AGONIST, SIGNIFICANTLY REDUCES LIVER FAT AND BODY WEIGHT IN OBESE SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A PHASE 1B/2A, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL () - Mar 11, 2021 - Abstract #NASHTAG2021NASH-TAG_85;
HM15211 was safe, well tolerated, and significantly decreased liver fat content and body weight in obese subjects with NAFLD by 8 and 12 weeks. The Phase 2b study is currently ongoing in US in patients with biopsy-confirmed NASH.
- HM15211 / Hanmi
[VIRTUAL] THERAPEUTIC EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST (HM15211) IN CDHFD-INDUCED MOUSE MODEL OF NASH AND FIBROSIS MICE () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1704;
Hence, better efficacy than acylated GLP-1/GIP further highlight weight loss uncoupled, direct therapeutic effect of HM15211. These results warrant on-going clinical studies for human efficacy translation.
- HM15211 / Hanmi
[VIRTUAL] ANTI-INFLAMMATION AND ANTI-FIBROSIS EFFECTS OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST TRIPLE AGONIST (HM15211) IN AMLN/TAA INDUCED MOUSE MODEL OF LIVER INFLAMMATION AND FIBROSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1661;
Together with the results in DIO mice, anti-inflammation and anti-fibrosis effects of HM15211 observed in AMLN/TAA mice suggest that HM15211 may be a novel therapeutic option for NASH and fibrosis. Human efficacy studies in patients with biopsy-proven NASH and fibrosis are on-going to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] ANTI-FIBROTIC EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST (HM15211) IN BDL-INDUCED MOUSE MODEL OF LIVER FIBROSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1659;
Hence, reduced expression of hepatic TGF-β and α-SMA suggest that the inhibition of hepatic stellate cell activation is essential for fibrosis improvement by HM15211. Further studies are needed to assess the clinical relevance of these findings.
- ||| efocipegtrutide (HM15211) / Hanmi
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD (clinicaltrials.gov) - Aug 10, 2020
P1, N=66, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
Further studies are needed to assess the clinical relevance of these findings. Recruiting --> Completed | N=48 --> 66 | Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Jun 2019 --> Mar 2020
- |||| efocipegtrutide (HM15211) / Hanmi
New P2 trial: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects (clinicaltrials.gov) - Aug 9, 2020
P2, N=112, Recruiting, Sponsor: Hanmi Pharmaceutical Company Limited
- HM15211 / Hanmi
[VIRTUAL] HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial (Poster Area) - Jul 29, 2020 - Abstract #EASLILCI2020EASL-ILC-I-2044;
HM15211 was safe and well tolerated during 12 weeks treatment in non-diabetic obese subjects with NAFLD.Treatment with HM15211 significantly decreased liver fat content and body weight in 8 and 12 weeks. Further development of HM15211 as a treatment for NASH is warranted
- HM15211 / Hanmi
[VIRTUAL] Anti-fibrotic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in BDL-induced liver fibrosis mice (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_1355;
Additionally, reduced levels of TGF-β and α-SMA suggest that the negative regulation of hepatic stellate cell activation is essential for fibrosis improvement by HM15211. Further studies are needed to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) exhibits anti-inflammatory and -fibrotic effects in AMLN/TAA induced liver inflammation and fibrosis mice (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_1354;
Therefore, HM15211 may be a novel therapeutic option for NASH by conferring well-harmonized pharmacologic effects of GLP-1, GIP, and Glucagon. Human efficacy studies are on-going to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in CDHFD-induced NASH and fibrosis mice (Salzburg Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_258;
Hence, more efficacy than FXR agonist in CDHFD mice further highlight the potential benefits of multi-targeting approaches of HM15211. Clinical studies in biopsy proven NASH patients are ongoing to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in healthy obese subjects (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1012;
Pharmacokinetic profiles were suitable for weekly administration. Clinical studies in patients with NAFLD/NASH are following.
- HM15211 / Hanmi
[VIRTUAL] Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in animal models of NASH and fibrosis (Channel 3) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-260;
Based on the beneficial effects in AMLN/TAA and BDL mice, HM15211 may provide therapeutic effects on fibrosis as well as NASH. Human efficacy studies are ongoing to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice () - May 18, 2020 - Abstract #ADA2020ADA_2147;
Therefore, consistent efficacy in various animal models including CDHFD mice suggests the beneficial effect of HM15211 on NASH and fibrosis. Efficacy studies in biopsy proven NASH patients are ongoing to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice () - May 18, 2020 - Abstract #ADA2020ADA_2122;
Therefore, in addition to steatosis improvement, HM15211 may provide anti-inflammatory and -fibrotic effect. Human studies are ongoing to assess the clinical relevance of these findings.
- HM15211 / Hanmi
[VIRTUAL] Antifibrotic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice () - May 18, 2020 - Abstract #ADA2020ADA_2121;
Considering the pathologic features of BDL mice (liver fibrosis without liver fat accumulation), these results demonstrate the direct anti-fibrotic effect of HM15211. Further studies are needed to assess the clinical relevance of these findings.